Anti-Coagulants - Norway

Norway

Highlights

In 2024, the revenue within the Anti-Coagulants market in Norway is forecasted to reach US$100.60m.
Looking ahead, it is expected that the revenue will demonstrate a compound annual growth rate (CAGR 2024-2029) of 6.57%, ultimately leading to a market volume of US$138.30m by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue within the Anti-Coagulants market, amounting to US$16.74bn in 2024.
Norway's anti-coagulant market is experiencing a surge in demand due to the country's aging population and high prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in Norway has been witnessing steady growth in recent years.

Customer preferences: Norwegian customers are increasingly demanding effective and safe anti-coagulant drugs. They prefer drugs that are easy to administer and have minimal side effects. Patients are also more inclined towards novel oral anti-coagulants (NOACs) over traditional warfarin due to the ease of use and lower risk of bleeding.

Trends in the market: The Norwegian Anti-Coagulants market has been growing steadily due to the increasing prevalence of cardiovascular diseases and the aging population. The market is witnessing a shift towards NOACs which have gained popularity due to their ease of use and lower risk of bleeding. The market is also witnessing increased competition from biosimilars and generic drugs which are more affordable than branded drugs.

Local special circumstances: Norway has a well-established healthcare system that provides universal access to healthcare services. The government plays a significant role in the healthcare sector, and the Norwegian Medicines Agency is responsible for regulating and approving drugs. The government negotiates drug prices with manufacturers, and this has led to a reduction in drug prices.

Underlying macroeconomic factors: Norway has a high standard of living, and its citizens have high purchasing power. This has led to increased spending on healthcare services and drugs. The Norwegian government has also increased its healthcare budget, which has led to increased spending on drugs. The aging population has also contributed to the growth of the Anti-Coagulants market as the elderly are more susceptible to cardiovascular diseases. In conclusion, the Anti-Coagulants market in Norway is witnessing steady growth due to the increasing prevalence of cardiovascular diseases and the aging population. The market is shifting towards NOACs and facing increased competition from biosimilars and generic drugs. Norway's well-established healthcare system, government regulation, and high purchasing power of its citizens have contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.